Duron F - Search Results

1

de la Blanchardière A, Duron F. de la Blanchardière A, et al. Among authors: duron f. Rev Med Interne. 1993 Feb;14(2):101-3, 105-6. doi: 10.1016/s0248-8663(05)81259-7. Rev Med Interne. 1993. PMID: 8378619 Review. French.

2

Intensive insulin therapy in insulin-dependent diabetes mellitus, the results of the diabetes control and complications trial.

Duron F. Duron F. Biomed Pharmacother. 1995;49(6):278-82. doi: 10.1016/0753-3322(96)82643-6. Biomed Pharmacother. 1995. PMID: 7579008 Review.

3

[Thyroid cancer revealed by a suppressive hot nodule].

Clément K, Lévy L, Coutris G, Hervé JP, Nordlinger B, Duhirel R, Féron R, Duron F. Clément K, et al. Among authors: duron f. Presse Med. 1991 Dec 14;20(43):2191-3. Presse Med. 1991. PMID: 1838153 Review. French.

4

Testosterone and its binding in hyperthyroid women before and under antithyroid drug therapy.

Loric S, Duron F, Guéchot J, Aubert P, Giboudeau J. Loric S, et al. Among authors: duron f. Acta Endocrinol (Copenh). 1989 Sep;121(3):443-6. doi: 10.1530/acta.0.1210443. Acta Endocrinol (Copenh). 1989. PMID: 2477979

5

[Pancreatectomy and diabetes].

Duron F, Duron JJ. Duron F, et al. Among authors: duron jj. Ann Chir. 1999;53(5):406-11. Ann Chir. 1999. PMID: 10389330 French.

6

Clinical value of thyrotropin binding inhibiting immunoglobulins (TBII) assay in hyperthyroidism.

Duron F, Talbot JN, Féron R, Aubert P, Milhaud G. Duron F, et al. Biomed Pharmacother. 1987;41(7):383-8. Biomed Pharmacother. 1987. PMID: 2895672

7

[Thyroid hormones, atherogenic and thrombogenic factors].

Thomas M, Charpentier G, Duron F, Aubert P, Dussert A, Alcindor LG, Pépin D, Béréziat G, Robert A. Thomas M, et al. Among authors: duron f. Rev Med Interne. 1981;2(1):83-9. doi: 10.1016/s0248-8663(81)80014-8. Rev Med Interne. 1981. PMID: 7232927 French. No abstract available.

8

[Indications and pharmacokinetic study of lithium carbonate in the treatment of the acute phase of Basedow's disease].

Charpentier G, Coutris G, Aubry P, Duron F, Rieu M, Thomas M. Charpentier G, et al. Among authors: duron f. Rev Med Interne. 1982;3(3):279-86. doi: 10.1016/s0248-8663(82)80032-5. Rev Med Interne. 1982. PMID: 6817403 French. No abstract available.

9

Use of the ligand immunofunctional assay for human insulin-like growth factor ((IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and igf-i bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics.

Lassarre C, Duron F, Binoux M. Lassarre C, et al. Among authors: duron f. J Clin Endocrinol Metab. 2001 May;86(5):1942-52. doi: 10.1210/jcem.86.5.7467. J Clin Endocrinol Metab. 2001. PMID: 11344189

10

Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year.

Talbot JN, Duron F, Féron R, Aubert P, Milhaud G. Talbot JN, et al. Among authors: duron f. J Endocrinol Invest. 1989 Oct;12(9):589-95. doi: 10.1007/BF03350008. J Endocrinol Invest. 1989. PMID: 2573625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters